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progression in 35 HIV-1 infected individuals from 7 monogamous and 6 polygamous partnerships within a
Rural Clinical Cohort in Uganda. The env-C2V3, gag-p24 and pol-IN genes were sequenced. Single genome
ampliﬁed half genome sequences were used to map recombination breakpoints. Three participants were
dually infected with subtypes A and D, one case with subtype A and A/D recombinant and the ﬁfth with 2
phylogenetically distinct A/D recombinants. Occurrence of A/D recombination was observed in two multiple
infected individuals. Rate of late stage WHO events using Cox regression was 3 times greater amongst
multiple infected compared to singly infected individuals (hazard ratio 3.35; 95% CI 1.09, 10.3; p=0.049). We
have shown that polygamous relationships involving subtype discordant partnerships was a major
contributor of multiple infections with generation of inter subtype recombinants in our cohort.P. Kaleebu).
 license.© 2010 Elsevier Inc. Open access under CC BY license.Introduction
The diversity of HIV-1 is greatest in Sub-Saharan Africa, with
currently 9 subtypes, 48 Circulating Recombinant Forms (CRFs) and
several Unique Recombinants Forms (URFs) identiﬁed (http://www.
hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html, March, 2010).
The high numbers of HIV-1 recombinants observed in these
populations (Dowling et al., 2002; Gale et al., 2006; Harris et al., 2002;
Herbinger et al., 2006; Hoelscher et al., 2002; Kiwanuka et al., 2008,
2009) might be an indication that infections with multiple subtypes
are frequent. Such populations might provide opportunities to further
understand how multiple infections and recombination occur and
their consequences to HIV vaccine development, disease progression
and scale up of anti-retroviral therapy.
Multiple infections (i.e. infectionwithmore than oneHIV-1 strain or
subtype) could be as a result of co-infection (simultaneous transmission
of two ormore distinct viruses before a speciﬁc HIV-1 immune response
is established) (Casado et al., 2007; Yerly et al., 2004) or superinfection
(consecutive transmission of a second virus or other strains after
seroconversion) (Altfeld et al., 2002; Blish et al., 2008; Fang et al., 2004;
Jost et al., 2002; Jurriaans et al., 2008; Kozaczynska et al., 2007; Pernaset al., 2006; Piantadosi et al., 2007; Ramos et al., 2002; Smith et al.,
2005a, 2005b, 2006; Streeck et al., 2008).
Over the past few years, there have been several reports of
existence of individuals with multiple infections (Altfeld et al., 2002;
Blish et al., 2008; Fang et al., 2004; Gottlieb et al., 2004; Herbinger
et al., 2006; Hoelscher et al., 2002; Jost et al., 2002; Piantadosi et al.,
2007, 2008; Sagar et al., 2003; Smith et al., 2005a; Streeck et al., 2008).
An earlier study in Mbeya region in Tanzania showed that the
prevalence of multiple infections in the low and high risk sexual
behaviour populations was 9% and 19% respectively (Herbinger et al.,
2006). In Rakai, Uganda, a 5.8% prevalence of multiple infections was
found in a low risk sexual behaviour cohort (Kiwanuka et al., 2009).
Lower rates of multiple infection (3%) were also reported in a cohort
of commercial sex workers in Burkina Faso (Manigart et al., 2004).
One consequence of HIV-1 multiple infections is recombination
between the two or more different strains in the host. A few studies
mostly based in one case each (Fang et al., 2004; Jobes et al., 2006;
Kozaczynska et al., 2007; Munoz-Nieto et al., 2008; Pernas et al., 2006)
have reported recombination in multiply infected individuals. This
recombination could result in aﬁtter virus partly as a result of the evasion
from host immune responses (Streeck et al., 2008). Multiple infections
have also been shown to lead to faster disease progression (Gottlieb et al.,
2004; Sagar et al., 2003). In our cohort which is a relatively low risk
population,we observe a high percentage of unique recombinant viruses
and it is of importance to understand how these arise.
Table 1
HIV-1 subtype distribution among partners.
Partner HIV-1 subtypes
Sample ID SC/RP date Sample date Linked Sequencing subtype DI
Monogamous Partnerships (MP)
Partnership1 env gag pol SGA
1 MP1-M Feb 26, 03 Oct 18, 04 linked A A
2 MP1-F Jul 13, 04 Jul 12, 04 A A
Partnership2
3 MP2-M Feb 9, 93 Mar 2, 00 linked C C
4 MP2-F Jan 23, 02 Mar 13, 02 C C
Partnership3
5 MP3-M Oct 7, 02 Jun 22, 04 linked A D
6 MP3-F Nov 9, 99 Feb 22, 01 A D
Partnership4
7 MP4-M P NA May 10, 05 linked D D
8 MP4-F Nov 7, 06 Oct 23, 08 D D
Partnership5
9 MP5-M Aug 23, 06 Feb 18, 09 linked D D
10 MP5-F P NA Dec 11, 02 D D
Partnership6
11 MP6-M P NA Jun 6, 07 linked A D
12 MP6-F Dec 2, 06 Nov 20, 08 A D
Partnership7
13 MP7-M Jan 6, 07 Dec 10, 08 linked A A
14 MP7-F P NA May 4, 98 A A
Polygamous Partnerships (PP)
Partnership1
15 PP1-M Mar 30, 97 Feb 7, 05 unlinked D D D A/D
16 PP1-F1 Dec 3, 02 Jun 20, 05 linked D D D A/D
17 PP1-F2 Mar 21, 01 Apr 9, 03 linked D D D A/D
18 PP1-F3 Oct 23, 96 Apr 9, 03 unlinked A A+A* A+A* A, A/D DI
19 PP1-F4 Jul 17, 93 Sep 15, 00 unlinked A+D D A+D A/D, A/D DI
Partnership2
20 PP2-M P 01-Oct-91 Oct 8, 08 unlinked D D
21 PP2-F1 P 20-Dec-90 Sep 24, 02 unlinked D D
22 PP2-F2 Feb 22, 99 Aug 2, 00 unlinked D D
Partnership3
23 PP3-M Mar 17, 96 Oct 17, 99 linked n/d D
24 PP3-F1 Sep 8, 95 Jan 27, 00 D D
25 PP3-F2 Sep 9, 95 Jan 27, 00 D D
Partnership4
26 PP4-M Jan 14, 97 Nov 24, 99 linked A D D D
27 PP4-F1 Feb 4, 99 Jul 6, 00 A D D D
28 PP4-F2 Mar 26, 96 Nov 17, 99 A D A+D D DI
Partnership5
29 PP5-M Nov 19, 91 Dec 6, 04 linked A D
30 PP5-F1 Dec 24, 00 Aug 30, 01 A D
31 PP5-F2 Mar 3, 92 Oct 5, 99 A D
Partnership6
32 PP6-M P 8-Nov-90 Jul 13, 00 unlinked A A A+D DI
33 PP6-F1 P 6-Apr-04 Feb 7, 01 unlinked A n/d A
34 PP6-F2 Mar 16, 95 Aug 2, 00 unlinked A A A+D A DI
35 PP6-F3 P 17-Jul-91 May 9, 07 unlinked A A A A
MP—monogamous partnership.
M—male.
F—female.
PP—polygamous partnership.
n/d—not done.
DI—dual infection.
P—prevalent at enrollment.
SC Date—estimated seroconversion date (mid-point between last HIV sero-negative test and ﬁrst HIV sero-positive date).
RP date—recruitment date for prevalent cases.
NA—not available.
SGA—single genome ampliﬁcation assay.
Sample date—collection date of sample used for subtyping.
Transmission linkage based on env-C2V3.
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superinfection in different groups such as commercial sex workers,
injection drug users andmenwho have sexwithmen (MSM) (Altfeld et
al., 2002; Blish et al., 2008; Casado et al., 2007; Fang et al., 2004; Gottlieb
et al., 2007; Gunthard et al., 2009; Jost et al., 2002; Koelsch et al., 2003;
Manigart et al., 2004; McCutchan et al., 2005; Piantadosi et al., 2007,
2008; Rachinger et al., 2008; Ramos et al., 2002; Sidat et al., 2008; Smithet al., 2006; Smith et al., 2004; Smith et al., 2005a,b; Steain et al., 2004;
Streeck et al., 2008; Yang et al., 2005; Yerly et al., 2004). Approximately
half of the reported cases of superinfectionwere acquiredwithin theﬁrst
year after seroconversion. The incidence of superinfection was found to
be 5% per year in a study in the USA amongst 78 ART-naïve individuals
between6and12months after primary infection (Smith et al., 2004). On
the other hand, a study inKenya in 36 high risk sexual behaviourwomen
Table 2
Socio-demographic characteristics, viral load and CD4 count at ﬁrst HIV seropositive
test.
Characteristic Single infected Multiple infected p Value
(n=30) (n=5)
n (%) n (%)
Agea
b25 years 8 (36%) 2 (40%) 1.00
25 years or more 14 (64%) 3 (60%)
Median agea [IQR] 27 (23, 34) 25 (23, 43) 0.901
Sex
Male 12 (40%) 1 (20%) 0.630
Female 18 (60%) 4 (80%)
Educationb
No schooling 3 (13%) 0 (0%)
Primary or Secondary education 21 (87%) 3 (75%)
Higher education 0 (0%) 1 (25%) 0.075
Main occupationb
Farmer 13 (54%) 2 (50%)
Other 11 (46%) 2 (50%) 1.00
Infecting cladec (env-C2V3/gag-p24)
A 6 (20%) n/a n/a
C 2 (7%) n/a
D 10 (33%) n/a
A/D recombinant 12 (40%) n/a
A/ D multiple infection n/a 5 (100%)
Median viral load log10 copies/ ml,
(95% CI)a, d
4.25 (3.76, 5.02) 4.98 (3.73, 5.52) 0.454
Median CD4 count [IQR]e 512 (145, 770) 425 (202, 636) 0.726
a Data missing for 8 singly infected individuals.
b Data missing for 6 singly infected individuals and 1 multiple infected individual.
c Data available for 30 singly infected individuals and 5 multiple infected individuals.
d First viral load measurement after seroconversion. This measurement was taken
between 0 and 69 months after seroconversion for singly infected patients and between
9 and 110 months after seroconversion in multiple infected individuals.
e Data missing for 4 singly infected patients.
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womenwere superinfected with a second virus (Piantadosi et al., 2007)
and superinfection occurred throughout the course of the ﬁrst infection.
Superinfection has been reported in individuals with cellular
immune responses to the initial virus, indicating an inability or failure
of immunity induced by the initial infection to confer protection
against subsequent challenges (Altfeld et al., 2002; Blish et al., 2008;
Piantadosi et al., 2007; Streeck et al., 2008). The role of neutralizing
antibodies in superinfection is also unclear with one study indicating
that low or non-existent broad neutralising antibody (NAb) responses
to HIV-1 may allow superinfection (Smith et al., 2006), while another
study (Blish et al., 2008) reported superinfection despite relatively
robust neutralizing antibody responses.
We are currently undertaking a number of studies in various low
and high risk cohorts in Uganda to characterize the host and viral
factors associated with multiple infection and superinfection. In this
study we report on the frequency of HIV multiple infections in a
group of individuals in polygamous and monogamous sexual
relationships. We report for the ﬁrst time that polygamous relation-
ships involving subtype discordant partnerships is a major contrib-
utor of multiple infections with a very efﬁcient generation of inter
subtype recombinants in our low risk rural cohort. The HIV disease
progression amongst the multiple and singly infected participants is
also assessed.Results
Socio-demographic and clinical characteristics of the study population
The estimated seroconversion dates for the incident cases or
known dates of enrollment for the prevalent cases and partnersubtypes data was tabulated (Table 1). Data on socio-demographic,
biological and clinical characteristics are given in Table 2. Age, sex,
education and occupation, as measured at the ﬁrst visit following
seroconversion, were similar between the singly (n=30) and
multiple infected individuals (n=5). The median viral load and CD4
count measured were also similar between these two groups at this
visit (Table 2). An estimate of the seroconversion date and/or follow-
up data was not available for four of these subjects and all subsequent
analysis are restricted to the 31 subjects with an estimate of the
seroconversion date.Determination of transmission linkage
To determine transmission linkages the phylogenetic relationships
between env-C2V3 and gag-p24 were analysed in all the 7
monogamous and 6 polygamous partnerships (n=35 participants).
Transmission linkage was assumed if sequences reliably clustered
together on phylogenetic trees (N80% bootstrap support) with no
other sequence beingmore closely related than the sequences were to
each other. Cloning and sequencing was not done on all samples, but
an average of 5–10 and 15–20 clones were sequenced in the env-C2V3
and gag-p24 genes per patient sample respectively. There was no end
point dilution done prior to PCR.
Transmissions were epidemiologically linked in all the 7 monog-
amous partnerships and 3 of the 6 polygamous partnerships analyzed
(Table 1, Fig. 1A, B, C). Five of the seven monogamous partnerships
were infected with pure subtypes based on env-C2V3/gag-p24
analysis including two infected with subtype A, two with subtype D
and one with subtype C. Infection with A/D recombinant viruses was
identiﬁed in two monogamous couples (Table 1, Fig. 1A, B). In the
three linked polygamous partnerships, one was infected with subtype
D and two had A/D recombinant viruses (Table 1, Fig. 1A, C).
Based on env-C2V3 sequencing, transmissions in the other 3 of
the six polygamous partnerships were unlinked (Table 1, Fig. 1A). In
the ﬁrst discordant partnership, PP1 (one male and 4 females), env-
C2V3 sequences from the husband (PP1-M) had a subtype D virus
whereas the ﬁrst and secondwives (PP1-F1 and PP1-F2 respectively)
were subtype discordant to their husband, both with a unique
recombinant subtype D virus. The third wife (PP1-F3) was infected
with a subtype A virus; and the fourth female (PP1-F4) in this
household was found to be multiple infected with subtype A and D
viruses. However gag-p24 sequences from the husband (PP1-M),
ﬁrst wife (PP1-F1) and second wife (PP1-F2) were all linked and
were classiﬁed as subtype D infection; however the third wife (PP1-
F3) was found to be multiple infected with two phylogenetically
distinct strains of gag-p24 subtype A viruses; and the fourth female
(PP1-F4) in this household was found to be infected with gag-p24
subtype D virus. (Table 1, Fig. 1C).
In the second discordant partnership, PP2, the husband (PP2-M)
and the two wives (PP2-F1 and PP2-F2) were infected with unlinked
subtype D viruses based on env-C2V3 sequencing (Table 1, Fig. 1A).
However, based on gag-p24 sequencing, all partners in polygamous
partnership 2 had linked subtype D viruses (Table 1, Fig. 1C).
In the third discordant partnership, PP6, the husband (PP6-M),
ﬁrst wife (PP6-F1), second wife (PP6-F2) and third wife (PP6-F3) all
had unlinked env-C2V3 subtype A viruses (Table 1, Fig. 1A). Analysis
of the gag-p24 sequences in polygamous partnership 6 showed that
the husband (PP6-M), the second (PP6-F2) and third wife (PP6-F3) all
had linked subtype A viruses. The gag-p24 sequence data for was
unavailable for the ﬁrst wife in polygamous partnership 6.
For quality control purposes, to be certain that patients from
epidemiologically unlinked patients were not cross-contaminated,
phylogenetic trees were constructed by including all direct and clonal
sequences from the env-C2V3 (Sup. Fig. 1A) and gag-p24 genes (Sup.
Fig. 1B).
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To investigate if the unlinked partners had viruses transmitted to
each other, the three polygamous partnerships that earlier showed
either subtype discordance or recombinant viruses in the env-C2V3 and
gag-p24 geneswere analysed further in the pol-IN gene. The pol-IN gene
that was analysed is a conservative 288 bp fragment that was ideal to
identify multiple infections. Polygamous partnership 2 that had
unlinked env-C2V3 and partnership 5 that had linked recombinant
viruses were not analysed in the pol-IN due to insufﬁcient sample
volume. There was no end-point dilution done and between 15 and 20
clones were sequenced from each patient sample. Analysis of the three
polygamous partnerships 1, 4 and 6 in the pol-IN by clonal sequencing
conﬁrmed one intrasubtype A and four intersubtype A/D multiple
infections. In polygamous partnership 1, the husband (PP1-M) and the
ﬁrst wife (PP1-F1) were infected with a linked subtype D virus. The
second wife (PP1-F2) had a discordant pol-IN subtype D virus whereas
the third wife (PP1-F3) was found to be with two strains of pol-IN
subtypeAviruses. The fourth female (PP1-F4) in this householdwasalso
multiple infected with subtype A and D viruses (Table 1, Fig. 1D).
Analysis of the pol-IN showed that there was transmission of viruses
between the husband (PP1-M) and the ﬁrst wife (PP1-F1) which were
not detected in the other three partners who all had discordant viruses
amongst themselves.
In polygamous partnership 4, the husband (PP4-M) and the two
wives (PP4-F1 and PP4-F2) had linked pol-IN subtype D infections; in
addition, a second pol-IN subtype A virus was detected in the second
wife (PP4-F2) (Table 1, Fig. 1D) probably indicating that this female
could have acquired this second virus from outside the partnership or
that this second virus was not detectable in the other partners.
In polygamous partnership 6, the husband (PP6-M) and the three
wives (PP6-F1, PP6-F2 and PP6-F3) were infected with linked pol-IN
subtype A viruses. In addition to this, the husband (PP6-M) and the
secondwife (PP6-F2)weremultiple infectedwitha second linkedpol-IN
subtype D virus (Table 1, Fig. 1D) also indicating that this second virus
was not detected in the ﬁrst female or that the husband and secondwife
acquired the second virus from outside of the partnership.
Analysis of the pol-IN amongst the subtype discordant partners
shows that there is possible transmission of viruses amongst the
partners and that there is a possibility of not detecting these viruses in
some of the partners.
To be certain that patients from epidemiologically unlinked
patients were not cross-contaminated, phylogenetic trees were
constructed by including all direct and clonal sequences from the
pol-IN gene for quality control (Sup. Fig. 1C).
Single genome ampliﬁcation assay (SGA)
Two multiple infections earlier detected in env-C2V3, gag-p24 and
pol-IN (intrasubtype A multiple infection PP1-F3 and intersubtype A/
D multiple infection PP1-F4) were further conﬁrmed following half
genome SGA analysis. The SGA analysis performed on samples from
polygamous partnership1 conﬁrmed that the third wife (PP1-F3) was
multiple infected with a pure subtype A virus and a recombinant A/D
virus. (Table 1, Fig. 2A–E). The recombinant A/D virus had earlier not
been detected in the pol-IN by cloning and sequencing. The fourth
female (PP1-F4) was also conﬁrmed to have two strains of A/D
recombinant viruses with different recombination break points and itFig. 1. A. Phylogenetic analysis of the env-C2V3 sequences (HXB2 location 6829–7334) of M
coloured PP1 (red), PP2- (purple), PP3 (dark blue), PP4 (light blue), PP5 (black) and PP6 (
partner. The phylogenetic plots do represent consensus sequences of the patients. B. Phylog
Partnerships (MP) 1–7. Bootstrap values greater than 80% are shown. M—male partner an
patients. C. Phylogenetic analysis of the gag-p24 sequences (HXB2 location 1123–1589) of Po
D. Phylogenetic analysis of the pol-IN sequences in Polygamous Partnerships PP1, 4 and 6 (in
than 80% are shown. M—male partner and F—female partner.was shown that there was a possible recombination event between
these two recombinants.
To analyse the recombinants based on a reference alignment of non-
recombinant sequences, half genome sequences (HXB2 4778-9547)
including the entire env genewere analysed in 5 fragments of awindow
size of approximately 1000 base pairs each. In the ﬁrst fragment (Fig. 2),
it was shown that the third wife (PP1-F3) was multiple infected with
subtype A and D. Her subtype D virus was also linked to the husband's
(PP1-M) and the other two wives' (PP-1-F1 and PP1-F2) viruses. The
fourth female (PP1-F4) in this household had a unique recombinant
subtype A virus in this fragment.
In thesecond fragment (Fig. 2B), thehusbandand threewives (PP1-F1,
2 and 3) had linked subtype A viruses. The thirdwife (PP1-F3) in addition
had a second phylogenetically distinct subtype A virus. The two
phylogenetically distinct strains of subtypeA in PP1-F3 had been detected
in pol-IN gene; thereby conﬁrming itwith SGA analysis. The fourth female
(PP1-F4) in the household had two subtype A and D viruses. In the third
fragment (Fig. 2C), the husband and three wives (PP1-F1, 2 and 3) had
linked subtype D viruses. The third wife (PP1-F3) in addition had a
subtype A virus. The fourth female (PP1-F4)was foundwith both subtype
A and D viruses which was consistent with the observation in the pol-IN
gene.
In the fourth fragment (Fig. 2D), the husbandand threewives (PP1-F1,
2 and 3) had linked subtype A viruses. The thirdwife (PP1-F3) in addition
had a second phylogenetically distinct subtype A virus. The fourth female
(PP1-F4) in this household had two viruses; a unique recombinant
subtype A and subtype D viruses. In the ﬁfth fragment, the husband and
two wives (PP1-F1 and 2) had linked subtype D viruses. The third wife
(PP1-F3) had a subtype A virus and the fourth female (PP1-F4) had a
discordant subtype D virus.
The bootscan analysis using pure reference sequences from
subtypes A, D and C is shown in Fig. 3 which also shows the ﬁve
fragments I–V that were phylogenetically analysed. In the ﬁfth
fragment, it was shown that in PP1-F3 only the parental pure subtype
A virus was identiﬁed. The bootscan and phylogenetic trees show that
there could have been recombination between the pure subtype A
virus and the recombinant A/D virus in PP1-F3. There was also a
possibility in the fourth female P1-F4 that there was recombination
between the two viruses as the ﬁrst and ﬁfth fragments clustered
together whereas the second, third and fourth fragments did not. To
control for contamination, all sequences generated from the SGAwere
included in one phylogenetic tree (Sup. Fig. 1D).
Adverse outcomes following seroconversion amongst singly and multiple
infected individuals
The median follow-up was 8 years (IQR 4, 14) amongst singly
infected individuals and 12 years amongst multiple infected indivi-
duals (IQR 7, 16). Themedian time to beginning ART or progressing to
a low CD4 count (≤250) following seroconversion was similar
amongst singly and multiple infected individuals: the median time
to beginning ART was 11 vs. 13 years for multiple and singly infected
individuals respectively (log rank p=0.572); the median time to low
CD4 count was 4 years vs. 6 years for multiple and singly infected
individuals respectively (log rank p=0.200). Conversely the median
time to experiencing WHO disease events (either two stage 3 events
or any single stage 4 event) (11 years for singly infected individuals)
was signiﬁcantly worse amongst multiple infected individualsonogamous Partnerships (MP) 1–7 and Polygamous Partnerships (PP) 1–6. All PPs are
green). Bootstrap values greater than 80% are shown. M—male partner and F—female
enetic analysis of the gag-p24 sequences (HXB2 location 1123–1589) of Monogamous
d F—female partner. The phylogenetic plots do represent consensus sequences of the
lygamous Partnerships (PP) 1–6. Bootstrap values greater than 80% are shown.M—Male.
cluding clone and direct sequences HXB2 location 4470–4807). Bootstrap values greater
117D. Ssemwanga et al. / Virology 411 (2011) 113–131
Fig. 1 (continued).
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Fig. 1 (continued).
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Fig. 1 (continued).
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121D. Ssemwanga et al. / Virology 411 (2011) 113–131(6 years) (log rank p=0.026). Median time to death could not be
calculated, and no difference was observed in mortality between
singly and multiple infected individuals (log rank p=0.713).
The rate of late stage WHO events (recurrent WHO stage 3 events
or a single WHO stage 4 event) was approximately 3 times greater
amongst multiple infected individuals compared to singly infected
individuals (hazard ratio 3.35; 95% CI 1.09, 10.3; p=0.049) (Table 3a).
We chose the category of WHO stage 4 or repeat stage 3 events
because this is used as criteria for commencing treatment in Uganda.
The mortality rate, rate of progressing to a low CD4 count (≤250) and
rate of commencing ART were also higher in the multiply infected
individuals compared to singly infected individuals although there
was no statistical evidence for these difference (Table 3a).
Adverse outcomes following seroconversion amongst singly and multiple
infected individuals restricted to only incident cases
The median follow-up was 7 years (IQR 4, 12) amongst singly
infected individuals and 10 years amongst multiple infected indivi-
duals (IQR 6, 14). The median time to death, beginning ART or
progressing to a low CD4 count (≤250) following seroconversion was
similar amongst singly and multiple infected individuals: the median
time to death was 14 years in singly infected individuals and 8 years
in multiple infected individuals (log rank p=0.445); the median time
to beginning ART was 11 vs. 10 years for multiple and singly infected
individuals respectively (log rank p= 0.805); the median time to low
CD4 count was 4 years vs. 6 years for multiple and singly infected
individuals respectively (log rank p=0.390). Conversely the median
time to experiencing WHO disease events (either two stage 3 events
or any single stage 4 event) (10 years for singly infected individuals)
was signiﬁcantly worse amongst multiple infected individuals
(5 years) (log rank p=0.011) (Table 3b).
Viral load and CD4 counts following seroconversion
We plotted the log10 viral load and CD4 count against time since
seroconversion for the 27 singly infected and 5 multiple infected
individuals (Fig. 4.). Only measurements prior to the initiation of ART
were included. There was a trend showing that the viral load increased
over timemore rapidly amongst themultiple infected individuals and a
decrease in CD4 count amongst multiple infected individuals appeared
to occur at a more rapid pace compared to singly infected individuals.
We also observed some two singly infected individuals that maintained
their viral loads in the elite controller range of 100–1000 copies. We
further observed that some individuals had viral loads that ﬂuctuate, an
observation noted over the years in other participants in our cohorts.
We were however unable to investigate the host and viral factors that
would explain this observation.
Discussion
As part of on-going studies, to determine the frequency of multiple
infections and super infections in our cohorts and relate this to host and
viral factors we investigated the contribution of monogamous and
polygamous partnerships. We have described the HIV transmission
dynamics in couples in a rural Ugandan cohort and found that while
monogamous partners had linked transmissions, three of the six
polygamous partnerships, involving three men and nine women in
total, were unlinked. We have identiﬁed multiple infections and in two
individuals we ﬁnd complex recombinant infections where there is
evidence of a shared virus infection between the man and three other
females in the partnership. We report the contribution of such partner-
ships to the generation of recombination viruses in this population.
In four of the seven monogamous partnerships, all with phyloge-
netically linked viruses, transmission was from the males to the
females as the males had seroconverted before the females. However,in ﬁve of the polygamous partnerships, there was a possibility that
transmissions were from one of the females who seroconverted
before all the other partners. It is possible that more multiple
infections in our study may have gone undetected due to techniques
used in identiﬁcation of multiple infections and viral dynamics during
the course of infection. Indeed in our study, we identiﬁed more
multiple infections when we combined both cloning and SGA
techniques implying that to detect multiple infections, several genes
must be analysed with the appropriate techniques.
All the subtype discordant viruses were observed in disclosed
polygamous partnerships and this partly explained why all the multiple
infections that were detected were from polygamous partnerships. We
were however unable to determine whether these multiple infections
were due to co-infectionwith two ormore viruses simultaneously or due
to super-infection since retrospective sampleshadearlier beenexhausted.
The observed discordance amongst the polygamous partners may
be due to polygamous partnerships formed after HIV infection, as in
the case of partnership 1 where the third wife (PP1-F3) is discordant
with a subtype A/A/A virus (env-C2V3/gag-p24/pol-IN) as opposed to
the other twowives' and husband's subtype D/D/D viruses (env-C2V3/
gag-p24/pol-IN). This observation was supported further by the third
wife (PP1-F3) having a dual infection with a recombinant A/D virus
and a pure subtype A virus. The subtype A virus was not detected in
the other partners but the recombinant A/D was detected in the other
three partners. This however does not rule out the possibility of HIV
negative partners acquiring viruses from different sources outside the
partnership. This may be a possible explanation for the observed
discordance in one gene and concordance in another gene as was the
case in PP2 and PP6. The absence of linkages in each individual may
probably imply acquisition of other viruses outside the sexual
network, however this is speculative. The env-C2V3 average genetic
distance in PP2 and PP6 was 17% and 15% respectively.
Themultiple infections amongst the polygamous partnersmay be an
indication that the polygamous individuals have more partners than
reported, further exposing them to super-infections. In this cohort over
the years, partnerships have been formed between already HIV positive
individuals (unpublished data) however no study has previously been
undertaken to assess whether re-infections do occur and the prevalence
of multiple infections amongst such individuals. Individuals in a known
monogamous or polygamous sexual network have also been reported to
move from one sexual partnership to another within the cohort
(unpublished data). An in-depth analysis on these individuals to
determine transmission dynamics has not been done. Another possible
explanation for the observed discordance may be that partners acquire
infections from outside the formal partnership (Trask et al., 2002). It is
also however possible that we may have missed detecting some viruses
in somepartners thatwere found to be discordantdue themethods used
to detect multiple infections.
We have been able to identify ﬁve cases of multiple infections in
our study, an observation that has beenmade in other studies (Gerhardt
et al., 2005; Kozaczynska et al., 2007; Pernas et al., 2006; Takehisa et al.,
1997, 1999; van der Kuyl et al., 2005). In our study, two individuals that
were dually infected possibly resulted into recombination events. Our
report further supports earlier studies thatmultiple infectionsare indeed
frequent when there is exposure. Further still triple infection with two
strains of subtype A and subtype C was reported in Tanzania (Gerhardt
et al., 2005); in Cameroon, infection with a group O virus, a subtype D
virus and subtype A/G recombinant virus was reported (Takehisa et al.,
1997, 1999). In Spain, an individual was found to have three
phylogenetically distinct strains of subtype B (Pernas et al., 2006) and
inNetherlandsan individualwas found toharbour twostrains of subtype
B and CRF01_AE (Kozaczynska et al., 2007; van der Kuyl et al., 2005).
If the observed multiple infections were due to superinfection
(which we were unable to determine) in the presence of an immune
response this raises a big challenge to the development of a vaccine.
There have been reports of superinfection in the presence of a cellular
122 D. Ssemwanga et al. / Virology 411 (2011) 113–131immune response (Altfeld et al., 2002; Jost et al., 2002; Streeck et al.,
2008; Yang et al., 2005). The role of neutralizing antibodies in
superinfection is also unclear with one study indicating that low or
non-existent broad neutralising antibody (NAb) responses to HIV-1
may allow superinfection (Smith et al., 2006), while another study
(Blish et al., 2008) reported superinfection despite relatively robust
neutralizing antibody responses.
As previously shown by others (Altfeld et al., 2002; Gunthard et al.,
2009; Hu et al., 2005; Jost et al., 2002; Ramos et al., 2002), our study
has shown both intrasubtype and intersubtype multiple infections,
which raises further concern of not only failure of cross subtype
protection but even intrasubtype protection.
There are previous reports that have shown recombination of
viruses amongst individuals with multiple infections (Fang et al.,
2004; Jobes et al., 2006; Kozaczynska et al., 2007; Munoz-Nieto et al.,
2008; Pernas et al., 2006). Our study further shows that there is a
possibility of on-going recombination amongst individuals with
multiple infections. This recombination due to multiple infections
was shown to have possibly occurred.
Recombination following multiple infections and the outgrowth of
the parental strains could also account for the failure to detect more
multiple infections in our study (Peeters et al., 1999; Songok et al.,
2004). If the super infecting strain is also transient with low levels of
replication, then this will most likely be undetected (Yerly et al.,
2004).
Multiple infections in some individuals was possibly detected in only
one genome region, an observation that has been reported to be due to
superinfection followed by recombination (Piantadosi et al., 2007). This
study in Kenya amongst 36 high risk women showed seven cases of
superinfection of which ﬁve cases had superinfection detected by
differences in only one gene. Further longitudinal analysis of these ﬁve
showed that superinfection was followed by recombination which
resulted in detection of both the recombinant virus co-circulating with
the ﬁrst infecting virus. In our observation, there is a possibility that
superinfection occurred that was followed by recombination which
resulted in detection ofmultiple infections in only one gene like itwas the
case in the Kenyan study.
The clinical signiﬁcance of multiple infections needs to be further
investigated; apart from the previously reported effects on disease
progression, multiple infections could complicate antiretroviral therapy
if already infected drug naive individuals get superinfection with ART
resistant viruses as earlier reported (Bezemer et al., 2008; Smith et al.,
2005b). Some reports indicate that some of the observed sudden viral
rebounds in patients on therapy is due to superinfection with a drug
resistant virus rather than drug resistance emerging in the primary
infecting virus (Jurriaans et al., 2008). Our study, though based on small
numbers has shown thatmultiple infectionswere associatedwith faster
disease progression as previously described in other studies (Gottlieb
et al., 2004; Sagar et al., 2003). Inour study,multiple infected individuals
had signiﬁcantly higher rates of late stageWHO events compared to the
singly infected individuals. In addition, viral loads increased and CD4
counts reduced more rapidly amongst themultiple infected individuals
compared to the singly infected individuals.
Conclusion
We report for the ﬁrst time that polygamous relationships
involving subtype discordant partnerships is a major contributor of
multiple infections with a very efﬁcient generation of inter subtypeFig. 2. A. Phylogenetic analysis of the ﬁrst SGA fragment (approx. 1000 bps) sequences in Po
and F—female partner. B. Phylogenetic analysis of the second SGA fragment (approx. 1000 bp
M-Male partner and F-Female partner. C. Phylogenetic analysis of the third SGA fragment (a
90% are shown. M—male partner and F—female partner. D. Phylogenetic analysis of the four
values greater than 90% are shown. M—male partner and F—female partner. E. Phylogen
Partnership 1. Bootstrap values greater than 90% are shown. M—male partner and F—femalrecombinants in our low risk rural cohort. These multiple infections
are probably due to super infection as a result of partnerships created
between already infected individuals or infections outside these
partnerships. We have further shown differences in disease progres-
sion between singly andmultiple infected individuals and the reasons
for these differences need to be further explored.
Materials and methods
Study setting and participants
In 1989 the then Medical Research Council Programme on AIDS in
Uganda established a General Population Cohort (GPC) encompassing
approximately 5000 adults drawn from a cluster of 15 villages in rural
Southwest Uganda. This cohort has been described in detail elsewhere
(Mulder et al., 1994). In 1990 a random selection of one-third of
seropositive adults identiﬁed in the initial GPC serosurvey roundwere
invited to enroll into the Rural Clinical Cohort (RCC), previously called
Natural History Cohort, as prevalent HIV cases (Morgan et al., 1997).
In 1999, 10 more villages were added to the GPC bringing the total
number of enrolled adults to about 10,000. Subsequent annual
serosurveys of the GPC have identiﬁed new HIV-seropositive
participants, who have been recruited as incident cases, the majority
of whom have estimated dates of seroconversion. Once enrolled into
the RCC they attend the study clinic every three months for clinical
history, examination and blood sampling. In the RCC, HIV infected
participants are encouraged to bring their partner(s) for voluntary
counseling and testing and possible enrollment.
Participants' selection
Blood samples were drawn from 35 HIV-1 infected randomly
selected participants, from 7 monogamous partnerships (MP) and 6
polygamous partnerships (PP) in the RCC. In the PP, 4 partnerships
had a husband with 2 wives, 1 partnership had a husband with 3
wives and another partnership had a husband with 4 wives. The
participants either had estimated seroconversion dates for the
incident cases or known dates of enrollment for the prevalent cases.
The seroconversion dates for the incident cases were estimated as the
midpoint between the date of the last sero-negative test and the date
of the ﬁrst sero-positive test.
RNA extraction and RT-Nested PCR
Viral RNA was extracted from cryo-preserved serum/plasma using
QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). Reverse
transcription and ﬁrst round PCR was done using QIAGEN OneStep
RT-PCR Kit (Qiagen, Hilden, Germany) to amplify the env-C2V3 and
gag-p24 genes using universal primers. For the analysis of the env-
C2V3, gag-p24 and pol-IN, end-point dilution was not performed prior
to PCR, cloning (designated “c” on the phylogenetic tree) and
sequencing.
Envelope analysis
First round PCR primers ED31 forward (5′ CCT CAG CCA TTA CAC
AGG CCT GTC CAA AG3′, at positions 6816–6844 of the HXB2 genome)
and primer ED33 reverse (5′ TTA CAG TAG AAA AAT TCC CCT C 3′, at
positions 7359–7380 of the HXB2 genome) (Delwart et al., 1995) andlygamous Partnership 1. Bootstrap values greater than 90% are shown. M—male partner
s) sequences in Polygamous Partnership 1. Bootstrap values greater than 90% are shown.
pprox. 1000 bps) sequences in Polygamous Partnership 1. Bootstrap values greater than
th SGA fragment (approx. 1000 bps) sequences in Polygamous Partnership 1. Bootstrap
etic analysis of the ﬁfth SGA fragment (approx. 1000 bps) sequences in Polygamous
e partner.
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T 3′, at positions 6829–6847 of the HXB2 genome) and Br reverse (5′
AAT TTC TAGGTC CCC TCC TGA 3′, at positions 7317–7334 of the HXB2
genome) (unpublished) were used to amplify a 505-bp env gene
product encompassing the env-C2V3 region.
The RT-PCR reaction contained; 10 μl 5× buffer, 2 μl dNTP mix, 2 μl
Taq enzyme mix, 0.5 μl RNase inhibitor, 3 μl 10uM Primer ED31, 3 μl
10 μM Primer ED33, 4.5 μl water and 25 μl of RNA. The cycling
conditions were 50 °C 30 min; 95 °C 15 min (95 °C 30 sec 54 °C
30 sec 72 °C 90 sec) ×40, 72 °C 10 min and 4 °C hold. The second
round PCR reaction contained 10 μl 10X PCR buffer, 4 μl 10 mM dNTP
mix, 10 μl 1.5 mM MgCl2, 2 μl of each 10 mM Primer Bf/Br, 0.6 μl Taq
Polymerase, 61.4 μl dH2O and 10 μl cDNA. The cycling conditions were1 cycle of 94 °C for 5 min, 35 cycles of 94 °C 10 sec, 50 °C 45 sec, 72 °C
1 min, then 1 cycle of 72 °C 10 min and a ﬁnal hold at 4 °C.
Gag analysis
The gag gene was ampliﬁed using 10 μM ﬁrst round PCR primers
H1G777 forward (5′ TCACCTAGAACTTTGAATGCATGGG 3′, at posi-
tions 777–801 of the HXB2 genome) and primer H1P202 reverse (5′
CTAATACTGTATCATCTGCTCCTGT 3′, at positions 1874–1898 of the
HXB2 genome) and second round 10 μMprimers H1Gag1584 forward
(5′ AAAGATGGATAATCCTGGG 3′, at positions 1123–1141 of the HXB2
genome) and primer g17 reverse (5′ TCCACATTTCCAACAGCCCTTTTT
3′, at positions 1566–1589 of the HXB2 genome) to generate a 460 bp
Fig. 3. Bootscanning of half genome sequences (approx. 4800 bps) from the 5 partners in Polygamous Partnership 1 (PP1-M, PP1-F1, PP1-F2, PP1-F3 and PP1-F4). PP1-F3 and PP1-F4 each
have 2 sequences and the other 3 partners each have one sequence. Query sequences are shown on the upper part of each partner's ﬁgure. Sequences to be compared with the query
sequence are indicated on the right side of the ﬁgure.When comparisons were done, SimPlot generates a graph of percentage of permutated trees obtained using a slidingwindow of 200
nucleotides. The y-axis gives the percentage of permutated trees M—male partner and F—female partner. The fragments I–V analysed are shown at the bottom of the ﬁgure.
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(Heyndrickx et al., 2000).
The env-C2-V3 and gag PCR products were visualised on a 1.5%
agarose gel to conﬁrm positive PCR ampliﬁcation and puriﬁed using
the QIAquick PCR Puriﬁcation Kit (Qiagen, Hilden, Germany).
Sequencing and phylogenetic analysis
The puriﬁed PCR products were directly sequenced in the sense
and antisense directions with primers Bf and Br for env-C2-V3 and
H1Gag1584 and g17 for gag. The DNA sequencing was carried out by
di-deoxy chain termination method by an in-house sequencingmethod using a Beckman capillary sequencer and an ABI capillary
sequencer. The chromatogram ﬁles were read using the Sequencher
4.6 program (GeneCodes, USA), and manually reﬁned in Se-Al
(available at http://evolve.zoo.ox.a.uk/software). Subtype reference
sequences of HIV-1 group M available from the Los Alamos Sequence
database (http://www.hiv.lanl.gov/content/sequence/NEWALIGN/
align.html, 2008) were used to automatically align the generated
sequences using ClustalX. The MEGA version 4.0 software package
(Tamura et al., 2007) was used to perform phylogenetic analysis and
the pairwise evolutionary distances were estimated using the HKY85
model (Hasegawa et al., 1985). The phylogenetic trees were
constructed by neighbor joining (Saitou and Nei, 1987) and the
Fig. 4. Viral load and CD4 count following HIV seroconversion. Only measurements taken prior to initiation of ART are depicted. Viral load (log10 copies/ ml) is plotted against time
since seroconversion (years) in the left panels. No viral loadmeasurements taken for ﬁve singly infected individuals. CD4 count is plotted against time since seroconversion (years) in
the right hand panels. CD4measurements were not available for one singly infected individual; for a further 3 singly infected individuals, CD4measurements were not available prior
to initiation of ART. S = singly infected individuals; M = multiple infected individuals.
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(1000 replicates) (Felsentein, 1985). Epidemiologically linked trans-
missions were deﬁned as those with bootstrap values N80%.
Sequences from the same partnership were given similar colors for
clarity purposes on the phylogenetic trees. Our Laboratory is enrolled
in two proﬁciency schemes such as Virology Quality Assurance and
Quality Control for Molecular Diagnostics for genotyping.
RT-PCR, clonal sequencing and phylogenetic analysis
Polygamous partners that had subtype discordant and recombi-
nant viruses were analyzed further in the pol-IN gene. Viral RNA was
extracted as earlier described and the pol-IN ampliﬁed using ﬁrst
round PCR primers Unipol5 (5′ TGGGTACCAGCACACAAAGGAATAG-
GAGGAAA-3′, at positions 3434–3765 of HIV-1LAI) and Unipol6 (5′
CCACAGCTGATCTCTGGCCTTCTCTGTAATAGACC 3′, at position 4483–
4516 of HIV-1LAI) and second round primers Unipol1 (5′ AGTGGATT-
CATAGAAAGCAGAAGT 3′, at positions 4052–4074 of HIV-1LAI) and
Unipol2 (5′ CCCCTATTCCTTCCCCTTCTTTTAAAA 3′, at positions 4363–
4388 of HIV-1LAI) to generate a 288 nucleotide sequence fragment
(Takehisa et al., 1998). The RT-PCR and second round reaction
mixtures and thermocycle conditions were the same as the env and
gag described above. The PCR products were cleaned as earlier
described and cloned into pGEM-T Easy Vector Systems (Promega
Corp., USA) and plasmids were transformed into High Efﬁciency
Competent cells according to manufacturer's instructions. The
transformants were cultured over-night on LB/Ampicillin/IPTG/X-
Gal blue-white screening plates. Between 10 and 20 positive clones
were selected for each sample from several PCR products and
sequenced using Unipol1 and Unipol2 primer sets. For the purpose
of clarity multiple clones were included for individuals with evidence
of intra/inter-subtype multiple infections.
Viral load measurements
HIV-1 RNA was tested using the Bayer VERSANT RNA 3.0 assay
(lower limit of detection 50 copies/ml) for baseline samples, and theRoche Amplicor MONITOR 1.5 for other samples (lower limit of
detection 400 copies/ml). The later assay replaced the former
following successful demonstration of the correlation between the
two assays.Single genome ampliﬁcation assay (SGA)
Participants that were found to have multiple infections were
analyzed further by SGA as described (Salazar-Gonzalez et al., 2008)
to conﬁrm multiple infections and recombination. In brief, cDNA was
endpoint diluted in 96-well plates such that fewer than 29 PCRs
yielded an ampliﬁcation product. According to a Poisson distribution,
the cDNA dilution that yields PCR products in no more than 30% of
wells contains one ampliﬁable cDNA template per positive PCR more
than 80% of the time. At least 10 half genome (positions 4768–9601 of
the HXB2 genome) sequences were generated from each sample. Viral
recombination analysis and location of breakpoints was done by
bootscanning in Simplot software (Lole et al., 1999). A sliding window
size of 1000 bp was used to analyse the 5000 bp half genome
sequences. Recombination analysis was done to determine if partners
had viruses with similar breakpoints or if there was recombination in
the multiple infected individuals.Statistical analyses
Analysis was restricted to those individuals, for whom clinical data
was available at more than one clinic visit. Socio-demographic,
biological and clinical outcomes were compared between singly and
multiple infected individuals using Fishers exact test or a Wilcoxon
rank sum test. Median times to experiencing an adverse event
(survival time) were estimates using Kaplan –Meier methods and a
log-rank test was used to compare survival between groups. Cox
regression was used to compare the rate of disease outcomes in the
singly and multiple infected individuals; due to small numbers only
univariate analyses were performed.
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